Published in Biomed Pharmacother on September 01, 2005
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 2.01
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology (2012) 1.01
The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J Med Chem (2009) 0.98
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J (2012) 0.88
Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother (2010) 0.86
A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J Biomed Biotechnol (2010) 0.84
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm (2011) 0.82
New candidate biomarkers in the female genital tract to evaluate microbicide toxicity. PLoS One (2014) 0.81
Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet Gynecol (2010) 0.80
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. J Biomed Biotechnol (2011) 0.79
Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol (2012) 0.78
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother (2004) 1.50
Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. J Hum Lact (2006) 1.41
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res (2011) 1.29
HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog (2008) 1.22
Antiviral potentials of medicinal plants. Virus Res (2007) 1.22
Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. J Biol Chem (2003) 1.20
Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell Microbiol (2006) 1.19
Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. J Cell Physiol (2002) 1.17
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. J Mol Recognit (2009) 1.10
Immunological control of herpes simplex virus infections. J Neurovirol (2013) 1.08
The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res (2011) 1.07
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07
Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate. Antimicrob Agents Chemother (2002) 1.07
Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother (2005) 1.04
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother (2005) 1.03
Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother (2011) 1.03
Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology (2003) 1.01
Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception (2002) 1.01
Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol (2012) 0.98
Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol (2011) 0.98
Secretion of the human T cell leukemia virus type I transactivator protein tax. J Biol Chem (2005) 0.98
DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol (2009) 0.97
Human T cell leukemia virus type I Tax activates CD40 gene expression via the NF-kappa B pathway. Virology (2005) 0.95
Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease. Biochem J (2003) 0.95
Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol (2004) 0.94
Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res (2011) 0.94
Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J Neurovirol (2004) 0.93
A novel high throughput quantum dot-based fluorescence assay for quantitation of virus binding and attachment. J Virol Methods (2007) 0.93
Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother (2010) 0.92
Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. J Neurovirol (2006) 0.92
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother (2003) 0.91
Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol (2003) 0.90
PMA-induced differentiation of a bone marrow progenitor cell line activates HIV-1 LTR-driven transcription. DNA Cell Biol (2007) 0.90
Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2010) 0.89
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2011) 0.89
Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2008) 0.89
Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. J Leukoc Biol (2007) 0.88
Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol (2004) 0.88
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J (2012) 0.88
HTLV-1 Tax nucleocytoplasmic shuttling, interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease. J Biomed Sci (2005) 0.88
Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome. Am J Gastroenterol (2003) 0.88
High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol (2004) 0.87
Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1. Antimicrob Agents Chemother (2010) 0.86
Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review. Am J Infect Dis (2009) 0.86
CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology (2006) 0.86
Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother (2010) 0.86
Substance abuse, HIV-1 and hepatitis. Curr HIV Res (2012) 0.85
Animal models of herpes simplex virus immunity and pathogenesis. J Neurovirol (2014) 0.85
Impact of Tat Genetic Variation on HIV-1 Disease. Adv Virol (2012) 0.85
Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation. J Neuroimmune Pharmacol (2010) 0.85
Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease. Front Biosci (Landmark Ed) (2009) 0.84
Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol (2006) 0.84
Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure. Biomed Pharmacother (2005) 0.84
A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J Biomed Biotechnol (2010) 0.84
Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection. J Immunol (2010) 0.84
Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed Pharmacother (2007) 0.83
Interaction of HTLV-1 Tax protein with calreticulin: implications for Tax nuclear export and secretion. Biomed Pharmacother (2007) 0.83
Differentiation of xenografted human fetal lung parenchyma. Early Hum Dev (2007) 0.83